An insertion/deletion polymorphism in the gene encoding angiotensin converting enzyme is not associated with generalised vitiligo in an English population

Archives of Dermatological Research

Volumn 297, Issue 2, 2005, Pages 94-98

  Akhtar, Samia ^a   Gavalas, Nikos G ^a   Gawkrodger, David J ^b   Watson, Philip F ^a   Weetman, Anthony P ^a   Kemp, E Helen ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Angiotensin converting enzyme; Autoimmunity; Gene polymorphism; Genetic susceptibility; Melanocyte; Vitiligo

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; ETHNOLOGY; FEMALE; GENE DELETION; GENE INSERTION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VITILIGO;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ENGLAND; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; T-LYMPHOCYTES, CYTOTOXIC; VITILIGO;

EID: 26444600141     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00403-005-0585-5     Document Type: Article

References (39)

1. Alkhateeb A, Stetler GL, Old W, Talbert J, Uhlhorn C, Taylor M, Fox A, Miller C, Dills DG, Ridgway EC, Bennett DC, Fain PR, Spritz RA (2001) Mapping of an autoimmunity susceptibility locus (AIS1) to chromosome 1p313-p322. Hum Mol Genet 11:661-667
2. Baharav E, Merimski O, Shoenfeld Y, Zigelman R, Gilbrund B, Yecheskel G (1996) Tyrosinase as an autoantigen in patients with vitiligo. Clin Exp Immunol 105:84-88
3. Bhatia PS, Mohan L, Pandey ON, Singh KK, Arora SK, Mukhija RD (1992) Genetic nature of vitiligo. J Dermatol Sci 4:180-184
4. Blomhoff A, Kemp EH, Gawkrodger DJ, Weetman AP, Husebye ES, Akselsen A, Lie BA, Undlien DE (2005) CTLA4 polymorphisms are associated with vitiligo in patients with concomitant autoimmune diseases. Pigment Cell Res 18:55-58
5. Cui J, Arita Y, Bystryn J-C (1995) Characterisation of vitiligo antigens. Pigment Cell Res 8:53-59
6. Czernobilsky H, Fiehn W, Ziegler R (1985) Comparison of serum angiotensin-converting enzyme in Graves' disease, toxic nodular goiter, and other thyroid conditions. Klin Wochenschr 63:518-522
7. Fain PR, Gowan K, LaBerge GS, Alkhateeb A, Stetler GL, Talbert J, Bennett DC, Spritz RA (2003) A genomewide screen for generalised vitiligo: confirmation of AIS1 on chromosome 1p31 and evidence for additional susceptibility loci. Am J Hum Genet 72:1560-1564
8. Gilhar A, Zelickson B, Ulman Y, Etzioni A (1995) In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol 105:683-686
9. Hann S-K, Nordlund J (2000) Vitiligo. Blackwell Science, Oxford, UK
10. Hooper NM (1991) Angiotensin converting enzyme: implications from molecular biology for its physiological functions. Int J Biochem 23:641-647
11. Jin SY, Park HH, Li GZ, Lee HJ, Hong MS, Hong SJ, Park HK, Chung JH, Lee MH (2004) Association of angiotensin converting enzyme gene I/D polymorphism of vitiligo in Korean population. Pigment Cell Res 17:84-86
12. 35 S-labelled recombinant human tyrosinase in a radioimmunoassay. J Invest Dermatol 109:69-73
13. Kemp EH, Ajjan RA, Waterman EA, Gawkrodger DJ, Cork MC, Watson PF, Weetman AP (1999) Analysis of a cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism in patients with vitiligo. Br J Dermatol 140:73-78
14. Kozlowski S, Corr M, Takeshita T, Boyd LF, Pendleton CD, Germain RN, Berzofsky JA, Margulies DH (1992) Serum angiotensin converting enzyme activity processes a human immunodeficiency virus 1 g160 peptide for presentation by major histocompatibility complex class I molecules. J Exp Med 175:1417-1422
15. Lang KS, Caroli CC, Muhm A, Wernet D, Moris A, Schittek B, Knauss-Scherwitz E, Stevanovic S, Rammensee H-G, Garbe C (2001) HLA-A2 restricted, melanocyte-specific CD8+ T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. J Invest Dermatol 116:891-897
16. Lin M-H, Tseng C-H, Tseng C-C, Huang C-H, Chong C-K, Tseng C-P (2001) Real-time PCR for rapid genotyping of angiotensin converting enzyme insertion/deletion polymorphism. Clin Biochem 34:661-666
17. Majumder PP, Nordlund JJ, Nath SK (1993) Pattern of familial aggregation of vitiligo. Arch Dermatol 129:994-998
18. McCormack WT, Bradley CA, Kristensen DL, She JX (2001) Genetics of vitiligo susceptibility: association studies of immune response genes. Pigment Cell Res 14:231
19. Nagamine K, Peterson P, Scott HS, Kudoh J, Minoshima S, Heino M, Krohn KJ, Lalioti MD, Mullis PE, Antonarakis, SE, Kawasaki K, Asakawa S, Ito F, Shimizu N (1997) Positional cloning of the APECED gene. Nat Genet 17:393-398
20. Nath SK, Majumder PP, Nordlund JJ (1994) Genetic epidemiology of vitiligo: multilocus recessivity cross-validated. Am J Hum Genet 55:981-990
21. Morris DA, Kissinger RM, Naughton GK, Bystryn J-C (1998) Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 90:783-789
22. Ochi Y, DeGroot LJ (1969) Vitiligo in Graves' disease. Ann Intern Med 71:935-940
23. Ogg GS, Dunbar PR, Romero P, Chen J-L, Cerundolo V (1998) High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 188:1203-1208
24. Okamoto T, Irie RF, Fujii S, Huang SK, Nizze AJ, Morton DL, Hoon DS (1998) Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol 111:1034-1039
25. Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll MW, Moss B, Rosenberg SA, Restifo NP (1999) Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci USA 96:2982-2987
26. Palermo B, Campanelli R, Garbelli S, Mantovani S, Lantelme E, Brazzelli V, Ardigo M, Borroni G, Martinetti M, Badulli C, Necker A, Giachino C (2001) Specific cytotoxic T lymphocyte responses against MelanA/MART1, tyrosinase and Gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 117:326-332
27. Papadopoulos K, Melander O, Orho-Melander M, Groop LC, Carlsson M, Hallengren B (2000) Angiotensin converting enzyme (ACE) gene polymorphism in sarcoidosis in relation to associated autoimmune disease. J Int Med 247:71-77
28. Rigat B, Hubert C, Alhenc-Getes F, Cambien F, Corvol P, Soubrier F (1990) An insertion/deletion polymorphism in the angiotensin I converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86:1343-1346
29. Rigat B, Hubert C, Corvol P, Soubrier F (1992) PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene. Nucleic Acids Res 20:1433
30. Rosenberg SA, White DE (1996) Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 19:81-84
31. Scholzen T, Armstorng CA, Bunnett NW, Luger TA, Olerud JE, Ansel JC (1998) Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems. Exp Dermatol 7:81-96
32. Scholzen TE, Stander S, Riemann H, Brzoska T, Luger TA (2003) Modulation of cutaneous inflammation by angiotensin converting enyme. J Immunol 170:3866-3873
33. Song YH, Connor E, Li Y, Zorovich B, Balducci P, Maclaren N (1994) The role of tyrosinase in autoimmune vitiligo. Lancet 344:1049-1052
34. Spritz RA, Gowan K, Bennett DC, Fain PR (2004) Novel vitiligo susceptibility loci on chromosomes 7 (ASI2) and 8 (ASI3), confirmation of SLEV1 on chromosome 17, and their roles in an autoimmune diathesis. Am J Hum Genet 74:188-191
35. Tastan HB, Akak A, Orkunoglu FE, Arca E, Inal A (2004) Association of HLA class I antigens and HLA class II alleles with vitiligo in a Turkish population. Pigment Cell Res 17:181-184
36. Vuk-Pavlovic Z, Rohrbach MS (1988) An in vitro model for the induction of angiotensin converting enzyme in sarcoidosis: possible parallels to the immune response Clin Exp Immunol 72:499-504
37. Woolf B (1955) On estimating the relation between blood group and disease. Ann Hum Genet 19:251-253
38. Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PD (2000) Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J Exp Med 192:1637-1644
39. Zamani M, Spaepen M, Sghar SS, Huang C, Westerhof W, Nieuweboer-Krobotova L, Cassiman JJ (2001) Linkage and association of HLA class II genes with vitiligo in a Dutch population. Br J Dermatol 145:90-94